Core Insights - Jaguar Health has received an initial payment of $16 million related to a US out-license agreement for Mytesi® and Canalevia®-CA1, with the potential for an additional $22 million through milestones and future payments [1] - The company is focusing on near-term milestones for its intestinal failure program, supported by significant results showing parenteral support (PS) reduction of 12% to 37% in an ongoing proof-of-concept study of crofelemer in pediatric patients [1] - Jaguar's rare-disease pipeline is currently in discussions for business development with potential partners, aiming for NDA-ready data within 12 to 18 months [1] Financial Updates - The initial payment of $16 million marks a significant financial milestone for Jaguar Health, with the potential for further payments totaling up to $22 million [1] Product Development - Crofelemer is being developed for the treatment of intestinal failure in patients with short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID), for which the company has received Orphan Drug Designation in both the US and EU [1] - The ongoing proof-of-concept study indicates a promising reduction in parenteral support, which is critical given the associated toxicities and lethal nature of PS [1] Upcoming Events - Jaguar Health is scheduled to present at the Sequire Investor Summit in Puerto Rico on January 22, and a replay of a previous fireside chat during the Lytham Partners Healthcare Investor Summit is available for viewing [1]